Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: Immunogenicity 5 years post-vaccination

Vaccine

Volumn 27, Issue 7, 2009, Pages 1062-1066

  McIntyre, Peter B ^a   Burgess, Margaret A ^a   Egan, Annemarie ^a   Schuerman, Lode ^b   Hoet, Bernard ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adult; Antibody persistence; Diphtheria; Pertussis; Tetanus

Indexed keywords

ADT; ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; PERTUSSIS ANTIBODY; PERTUSSIS VACCINE; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TETANUS; VACCINATION; VERO CELL;

ADULT; AGED; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS;

EID: 58549098277     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.102     Document Type: Article

References (27)

1. Brotherton J., McIntyre P., Puech M., Wang H., Gidding H., Hull B., et al. Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell 28 Suppl. 2 (2004) S42-S45
2. Centers for Disease Control and Prevention (CDC). Pertussis-United States, 1997-2000. MMWR Morb. Mortal Wkly. Rep. 2002;51:73-6.
3. Thomas P.F., McIntyre P.B., and Jalaludin B.B. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 173 (2000) 74-76
4. De Serres G., Shadmani R., Duval B., Boulianne N., Dery P., Douville Fradet M., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 182 (2000) 174-179
5. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. (2003), Australian Government Department of Health and Ageing, Canberra
6. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown K.H., et al., Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal Wkly. Rep. 2006;55(RR-3):1-34.
7. De Serres G. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep 26 (2000) 1-8
8. Calendrier vaccinal 2006. Avis du Conseil supérieur d'hygiène publique de France. Bulletin Epidémiologique Hebdomadaire 2006:29-30.
9. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut 2006. Epidemiologisches Bull 2006;30.
10. World Health Organization, Vaccine preventable diseases monitoring system. Immunization schedules by antigen, selection centre. http://www.who.int/immunization_monitoring/en/globalsummary/ScheduleSelect.cfm [updated 22.12.2006].
11. National Health and Medical Research Council. The Australian Immunisation Handbook. 9th edition (2008), Australian Government Department of Health and Ageing, Canberra
12. Forsyth K.D., Wirsing von Konig C.H., Tan T., Caro J., and Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25 (2007) 2634-2642
13. Campins-Marti M., Cheng H.K., Forsyth K., Guiso N., Halperin S., Huang L.M., et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20 (2001) 641-646
14. Turnbull F.M., Heath T.C., Jalaludin B.B., Burgess M.A., and Ramalho A.C. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 19 (2000) 628-636
15. McIntyre P.B., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., and Schuerman L.M. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 3 (2004) 380-385
16. Cheuvart B., Burgess M., Zepp F., Mertsola J., Wolter J., and Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 23 (2004) 336-342
17. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20 (2001) 63-75
18. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44 (2007) 1271-1277
19. Granstrom M., and Granstrom G. Serological correlates in whooping cough. Vaccine 11 (1993) 445-448
20. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21 (2003) 3542-3549
21. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353 (2005) 1555-1563
22. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190 (2004) 535-544
23. Zepp F., Knuf M., Habermehl P., Mannhardt-Laakmann W., Howe B., and Friedland L.R. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 149 (2006) 603-610
24. Theeten H., Rümke H., Hoppener F.J., Vilatimó R., Narejos S., Van Damme P., et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 23 (2007) 2729-2739
25. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38 (2000) 800-806
26. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., and Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53 (2006) 106-113
27. Barreto L., Guasparini R., Meekison W., Noya F., Young L., and Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 25 (2007) 8172-8179